U.S. Department of Health and Human Services Food and Drug Administration

MEDWATCH

FORM FDA 3500A (2/19)

For use by user-facilities, importers, distributors and manufacturers for MANDATORY reporting

Page 1 of 3

See PRA statement on reverse.
Mfr Report # AGI-30112021-74
UF/Importer Report #

FDA Use Only
F/Importer Report #
Ifr Report # AGI-30112021-74
See PRA statement on reverse.

	pts of "dd-mmm-yyyy" please use		r month	3. Dose		Frequen	cy Roi	ute Used		
•	igit year; for example, 01-Jul-201	8.		#1						
A. PATIENT INF				#2			., , 1= =			
1. Patient Identifier	_	3.Gender	4. Weight			py Dates (give le ur best estimate.)	·	iagnosis foi	Use (Indication)	
PATT	31	Female	□lb	#1 Start	and stop) or you	a. Door Gouillaid.)	#1			
la saufi l	□ vveek(s) □ Day(s)	Male	□kg	#1 Start						
In confidence	or Date of Birth:	□Intersex	9							
	01-Jan-1990	□Transgender		#2 Start			#2			
		☐ Prefer not to		#2 Stop						
	C Para	disclose		1						
5. Ethnicity	6. Race	ion or Alaska- N								
☑ Hispanic/Latino ☐ Asian ☐ American Indian or Alaskan Native ☐ Black or African American ☐ White			6. Product Type (Check all that apply) 7				Expiration Da	ite		
■ Not Hispanic/Latino	Native Hawaiian or Othe			#1 DOTC #2 DOTC #						
B. ADVERSE_EV	/ENT OR PRODUCT PRO				mpounded	☐ Compounded				
1. Type of Report					eneric	Generic	#2			
☐ Adverse event	☐ Product proble	em (e.g. defects/r	malfunctions)		osimilar	Biosimilar				
2. Outcome Attribute	ed to Adverse Event (check all	that apply)			oated After Us or Dose Red			t Reappeared After		
☐ Death Date of	death:									
☑ Life-threatening	□D	isability or Perman	ent Damage	#1 Tes	□No	Doesn't Apply	#1 Yes	□No	□ Doesn't Apply	
☐ Hospitalization (in	nitial or prolonged)	ongenital Anomaly	Birth Defects	#2 □ Yes	□No	□ Doesn't	#2 □ Yes	□No	□ Doesn't	
Other Serious or	Important Medical Events			#Z LI TES	□ INU	Apply	#ZLITES	□ NO	Apply	
<u> </u>	ntion to Prevent Permanent Impa	•								
3. Date of Event (do		of this Report (dd		D. SUSPE	CT MEDIC	AL DEVICE				
5. Describe Event or	lov-2021	30-Nov-20	21	1. Brand Nai	me					
J. Describe Event Of	FIODIEIII			0-0	Davie No			los p		
				za. Commor	n Device Nam	е		2b. Proce	oue	
				3. Manufacti	urer Name, Ci	tv and State				
6. Relevant Tests/La	boratory Data	Date (dd-mmm)-VVV)	-		,				
			17117							
				4. Model #		Lot #		5. Operat	or of Device	
								☐ Health	Professional	
			· ·	Catalog #		Expiration I	Date	☐ Patient	/Consumer	
				Ondata		11	un nen	Other		
7 Other Polovent III	story, Including Preexisting Me	edical Conditions		Serial #		Unique Idei	ntifier (UDI) #	Otner		
	story, including Preexisting Me ancy, smoking and alcohol use, liv		s. etc.)	6a. If Implan	ted , Give Da	l te		6b. If Evr	planted, Give Date	
(g.,aorgioo, progrid	, s	Thursday problems	, 5.0.,	Tall in implant	, 0 Da				Siro Date	
					7a. Is this a Single-use Device ☐ Ye				s, Enter Name and	
				that was Reprocessed and					ess of	
					Reused on a Patient? 8. Was this device serviced by a third party?				Reprocessor	
C SUSPECT PE	CODUCTS			-		ed by a third part	y?			
C. SUSPECT PR	Anufacturer/Compounder			☐ Yes ☐ No	山 Unknown					
#1 – Name and Streng	•	#1 – NDC # or U	nique ID	9. Device Av	ailable for Ev	valuation ?				
Crocin	-		•			to Manufacturer o	on :			
#1 – Manufacturer/Co	mpounder	#1 – Lot #		•		Products and Th				
]						
#2 – Name and Streng	gth	#2 – NDC # or U	nique ID							
#2 – Manufacturer/Co	mnounder	#2 – Lot #		-						
π∠ – ivianula∪tulei/C0	impounder	#2 - LUI #								
2. List Medical Produ	uct and Treatment Given at the	Same Time Of the	Event and	E. INITIAL	REPORT	ER				
Date		E. INITIAL REPORTER 1. Name and Address								
No concomitants used/reported									ne : TEST	
				Address :						
							1 -			
				City:			State/Proving		0.05.4455/01	
	rt does not constitute an admission			ZIP/Postal Co	ode:	Email	Country: UN	HEDSTATE	S OF AMERICA	
tacility, importer, distri	ibuter, manufacturer or product c	aused or contribute	d to the event.		efeccion alo	Email :		4 Initial D	antan Alaz Czart	
				2. Health Pr	oressional?	3. Occupation Physician			porter Also Sent	
				☑ Yes	□No	,5.5.6		Report to ☐ Yes ☐ N		
				□ 162	LI NO	1		L res LIN	O LI OTIK	

MEDWATCH

FORM FDA 3500A (2/19) (continued)

For use by user-facilities, importers, distributors and manufacturers for MANDATORY reporting

Page 2 of 3

FDA Use Only	

F. FOR USE BY	USEF	R FACILITY/IMI	PORTER (D	evices Only)	H. DEVICE MANU	JFACTURERS ON	NLY		
1. Check One			2. User Facilit	y/Importer Reporter	1. Type of Reportable		2. If Follow-up, What Type?		
☐ User Facility ☐ Importer Number			Number		☐ Death		☐ Correction		
3. User Facility or Im	porter	Name/Address			☐ Serious Injury		Additional Information		
					☐ Summary Report		Response to FDA Request		
					No. of events summarized		Device Evalution		
					3. Device Evaluated b	y Manufacturer?	4. Device Manufacture Date		
4. Contact Person 5. Phone Nu				ber	☐ Yes ☐ No	•			
C. Data Hara Facility on Jan.				lo Barrate Barrat	(Attach page to explain wheel (Attac	hy not) or provide code:			
6. Date User Facility or Importer Became Aware of Event 7. Type of Report ☐ Initial ☐ Follow-up #			8. Date of This Report	■ Not Returned to Mar	nufacturer	5. Labeled for Single Use?			
		Follow-up #			☐ Evaluation Summary		☐ Yes ☐ No		
9. Approximate	10.00	dverse Event Probl	om		6. Adverse Event Prol	olem (Refer to coding	manual)		
Age of Device		h Effect -	Health E	Effect -	Health Effect -		Health Effect -		
	Clinica	linical Code Impa edical Device Com		Code	Clinical Code		Impact Code		
				nent	Medical Device		Component Code		
	FIODIE	em Code	Code		Problem Code				
11. Report Sent to FI	DA?	12. Location Wher	e Event Occur	red	Type of Investigation				
Yes					Investigation				
□No					Findings				
					Investigation Conclusions				
13. Report Sent to Manufacturer?					7. If Remedial Action	Initiated Check Tyme	8. Usage of Device		
Yes						Notification	B. Usage of Device ☐ Initial Use of Device ☐ Reuse ☐ Unknown		
□ Yes □ No					Repair	☐ Inspection			
14. Manufacturer Na	me/Ad	dress				☐ Patient Montitoring			
					Relabeling	☐ Modification/	9. If action reported to FDA under		
						Adjustment	21 USC 360i(f), list correction / removal reporting number :		
					Others:		,g		
G. ALL MANUFA	ACTU	RERS			10.Additional Manufac	cturer Narrative			
1. Contact Office (an	nd Man	ufacturing Site for		Report Source					
or Compounding	Outso	urcing Facility		Check all that apply) Troreign					
Name : PTEST1			4	Study					
Farail Address		:4@:		Literature					
Email Address : udup	ı.puron	it@arisgiobai.com		Consumer					
Address : PTEST1, T				Health Professional					
AMERICAN SAMOA,	12345		I	User Facility					
<u></u>				☐ Company					
Phone Number : cont	inued			Representative					
Compounding Outsou	urcina F	Facility 503B? Cha	ook	Distributor/Importer					
		•	if applicable	Other (Please list):					
Outsourcing Facility :	PTEST	Γ1	7.	Adverse Event Term(s)	11. Correction Data				
3. Date Received by	'	4.		ver (Fever(10016558),					
Manufacturer (dd-	-mmm-		P	rexia(10037660))					
<i>yyyy)</i> 30-Nov-2021		ANDA # IND #							
5. If IND/PreANDA, O	Give	BLA #							
Protocol #		PMA/							
		510(k) #							
		Check all that							
6. Type of Report		Combination							
(Check all that ap			PreANDA 🔲						
□ 5-Day □ Po □ 7-Day ☑ In	eriodic	;		Manufacturer Report					
=	nitiai ollow-l	In :	OTC 🗖	Number					
□ 13-Day □ F	CIIOW-C	Compounded	d Product 🗖 A	GI-30112021-74	Department of Health a	and Human Services	OMB Statement: "An agency may not		
	only to	o requirements of t	he Paperwork	Reduction Act of 1995.	Food and Drug Adminis		conduct or sponsor, and a person is not		

This section applies only to requirements of the Paperwork Reduction Act of 1995. This section applies only to requirements of the Paperwork Reduction Act of 1995. The public reporting burden for this collection of information has been estimated to average 73 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act(PRA) Staff
PRAStaff@fda.hhs.gov

OMB Statement: "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB contact number."

Mfr. Report #: AGI-30112021-74

PTEST1

Date of This Report: 30/Nov/2021 09:21:28

C. SUSPECT AND OTHER PRODUCT(S) (Cont..)

C.1. Name, Strength, Manufacturer/Compounder (from product label)

: Crocin (CROCIN, test) (Suspect) C.1.1. Name and Strength

EVENT INFORMATION

Seq No. : 1 Reported Term fever **Onset Date** : 30-Nov-2021

Event Type Adverse Event/Reaction Recovering/Resolving OutCome

UNITED STATES OF AMERICA **Country Of Detection**

Severity Severe

Event Seriousness

Seriousness Yes Death? No

Required Intervenation No Information

Life Threatening? Yes

Congenital Anomaly/Birth Defect? No Information Caused/Prolonged Hospitalization No Information No Information Disability/Permanent Damage? Yes

Other Medically Important Condition

Other Medically Important Condition Info

Test

G. ALL MANUFACTURERS

G.2. Phone Number

1111-11111-123456